Crystalys Therapeutics secured an oversubscribed $130 million Series B to move dotinurad toward US and EU commercialization after advancing through late-stage development. The funding supports two Phase 3 registration-directed trials—RUBY and Topaz—as well as the Phase 2 AMETHYST study, according to the company. Dotinurad, an oral URAT1 inhibitor designed for once-daily dosing, targets gout patients with unmet needs. The company said proceeds fund clinical development and commercialization preparation while targeting multiple regulatory and milestone events. The round led by Frazier Life Sciences with participation from several healthcare investors underscores continued capital appetite for mechanism-driven immunometabolic and inflammation programs with clear regulatory endpoints.